|
Feb 18, 14:10
|
Pfizer Colorectal Cancer Trial Win Adds Weight To Oncology Turnaround Story
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 13:08
|
Pfizer (PFE) Valuation Check After Recent Share Price Rebound And Mixed Earnings Signals
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 09:26
|
Fallopian Tube Cancer Market Research Report 2026: AstraZeneca, GlaxoSmithKline, Pfizer and Roche Expand Portfolios and Invest in Novel Therapeutics & Companion Diagnostics - Forecasts 2025-2035
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 17:42
|
Pfizer: The Rebound Looks Unsustainable
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 15:30
|
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 13:09
|
Pfizer Trial Updates Test Investor Views On Pipeline And Valuation
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 13:00
|
ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 12:00
|
How Is The Market Feeling About Pfizer Inc?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 11:45
|
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 11:15
|
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 07:48
|
Pfizer Announces Topline PFS Survival Results From Cohort 3, Separate Randomized Cohort Of Pivotal BREAKWATER Trial, Evaluating BRAFTOVI In Combination With Cetuximab And FOLFIRI In mCRC With BRAF V600E Mutation
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 04:34
|
2 Value Stocks Worth Your Attention and 1 We Brush Off
|
N/A |
—
|
—
|
No analysis
|
|
Feb 14, 19:45
|
What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?
|
N/A |
—
|
✓
|
# PFE News Report — 2026-02-14
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | PFE |
| **Date** | 2026-02-14 |
| **Total Articles**...
|
|
Feb 14, 19:04
|
Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25
|
N/A |
—
|
—
|
No analysis
|
|
Feb 14, 06:28
|
Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 15:13
|
Pfizer Obesity And Hemophilia Advances Spark Fresh Interest In Valuation
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 15:07
|
Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 14:57
|
Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 11:52
|
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 17:00
|
Kahn Brothers Reduces Stake in Pfizer Inc by 21.66%
|
N/A |
—
|
✓
|
# PFE News Report — 2026-02-12
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | PFE |
| **Date** | 2026-02-12 |
| **Total Articles**...
|
|
Feb 12, 15:38
|
MDGL Strengthens MASH Franchise With New Genetic Approaches
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 13:00
|
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 04:30
|
Pfizer Hemophilia And Obesity Updates Reshape Growth And Valuation Outlook
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 18:30
|
Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 15:35
|
Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 13:01
|
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
|
N/A |
—
|
—
|
No analysis
|